What question did this study set out to answer?

The research aims to systematically identify and analyze the bioactive components in Bawei Chenxiang Powder that target beta1-adrenergic receptors for cardiovascular treatments.

January 25, 2026

Systematic Identification and Recognition Analysis of Beta1‐Adrenergic Receptor Targeting Material Basis in Tibetan Medicine Formula Bawei Chenxiang Powder

Key Points

The research aims to systematically identify and analyze the bioactive components in Bawei Chenxiang Powder that target beta1-adrenergic receptors for cardiovascular treatments.
Engineered a fusion protein linking the kinase domain of EGFR to the C-terminus of beta1-AR.
Immobilized the fusion protein onto ibrutinib-modified silica gels.
Prepared a column with the immobilized beta1-AR and evaluated its stability and specificity using retention behavior analysis.
Conducted mass spectrometry to screen BWCP constituents targeting beta1-AR.
Identified eight key constituents of BWCP that target beta1-AR, including 6-hydroxy-2-(2-phenylethyl) chromone and catechin.
Measured association constants for these compounds, indicating their binding affinity to beta1-AR.
Molecular docking revealed that stabilization of the compound-beta1-AR complexes relies on various interactions, such as hydrogen bonding and van der Waals forces.

Abstract

ABSTRACT Bawei Chenxiang Powder (BWCP) is a Tibetan medicine formulation used to treat cardiovascular diseases, has demonstrated clinical efficacy though its material basis remains unclear. In clinical trial, β 1 ‐adrenergic receptor (β 1 ‐AR) has been recognized as a key therapeutic target in cardiovascular disease treatment. So, in this work, we engineered a fusion protein by linking the kinase domain of epidermal growth factor receptor (EGFR) to the C‐terminus of β 1 ‐AR, which was subsequently immobilized onto the ibrutinib‐modified silica gels. Following column preparation by packing the β 1 ‐AR immobilized silica into a stainless‐steel column, the specificity and stability of β 1 ‐AR column were evaluated through the retention behavior analysis of atenolol, esmolol, and metoprolol for characterization. Then, using the β 1 ‐AR column combined with MS/MS, eight BWCP constituents targeting β 1 ‐AR were screened and identified: 6‐hydroxy‐2‐(2‐phenylethyl) chromone, taxifolin, myristicin, costunolide, dehydrocostus lactone, gallic acid, 3,4‐dihydroxybenzoic acid (DHBA), and catechin. The association constants of above screened compounds with immobilized β 1 ‐AR were (6.75 ± 0.05) × 10 4 , (13.2 ± 0.60) × 10 4 , (3.82 ± 0.18) × 10 4 , (145.13 ± 1.50) × 10 4 , (199.77 ± 0.30) × 10 4 , (13.8 ± 0.04) × 10 4 , (9.30 ± 0.14) × 10 4 , (31.4 ± 0.76) × 10 4 M −1 , respectively. Molecular docking results indicated that the compound‐β 1 ‐AR complexes stabilization primarily involves hydrogen bonding, van der Waals interactions, Pi‐alkyl, and Pi‐Pi stacking. A survey of DrugBank showed that catechin have well defined effects against cardiovascular diseases. DHBA and taxifolin are potential drug leads under experimental. These confirmed the reliability of the screened compounds by the immobilized β 1 ‐AR. To our knowledge, this work establishes the first systematic identification of BWCP's bioactive components targeting β 1 ‐AR, providing a pharmacological foundation for developing novel cardiovascular therapeutics derived from this traditional formulation.

Bookmark

Cite This Study

Chen et al. (Thu,) studied this question.

synapsesocial.com/papers/6975b38dfeba4585c2d6ef74 https://doi.org/https://doi.org/10.1002/jmr.70022

Bookmark